While other anti-tau mAbs have failed to show an effect on disease progression in AD (22, 23), JNJ-63733657 differs from these other antibodies in that it binds to the proline rich domain in the mid-region of tau rather than the N-terminus. Here, MAPT is linked to Alzheimer disease.